After a median 10 years of follow-up, the BC2001 trial confirmed that adding chemotherapy to RT improves salvage cystectomy rate, locoregional control, and bladder cancer–specific survival over RT alone in muscle-invasive bladder cancer.
Although BCG remains the primary therapy for patients with NMIBC, many patients have disease that is resistant to this treatment or relapses. Optimal treatment for patients with what is now considered BCG-unresponsive NMIBC remains to be established.
Prostate cancer can be subtyped based on cell of origin, into luminal A, luminal B, and basal cell subtypes, according to a new study (Abstract 3). Luminal B prostate cancer has the poorest prognosis, but also derives the most benefit from ADT.
Adding mitoxantrone/prednisone to ADT in patients with high-risk prostate cancer who underwent prostatectomy increased the risk of leukemia and did not improve overall or prostate cancer–specific survival in a randomized phase III trial.
At the present time, genetic evaluation guidelines for prostate cancer primarily focus on BRCA1 and BRCA2 testing. The overall risk of prostate cancer has been reported up to 3.8-fold for men who carry BRCA1 mutations and up to 8.6-fold for men who carry BRCA2 mutations.